KCM
ESPR icon

Kennedy Capital Management’s Esperion Therapeutics ESPR Stock Holding History

Kennedy Capital Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-239,054
Closed -$2.99M – 734
2016
Q4 		$2.99M Buy
239,054
+169,177
+242% +$2.01M 0.05% 529
2016
Q3 		$968K Buy
+69,877
New +$792K 0.02% 654

Other funds holding ESPR

PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Kennedy Capital Management's ESPR Position: Q1 2017 in Review

Kennedy Capital Management sold out of Esperion Therapeutics (ESPR) in Q1 2017, closing a stake of 239,054 shares — an estimated $2.99M sold.

Kennedy Capital Management first reported a position in ESPR in Q3 2016 and held it in 2 quarters. The position peaked at $2.99M in Q4 2016. 119 funds tracked by Wall St. Rank hold ESPR as of Q1 2017.

  • Kennedy Capital Management reported no remaining Esperion Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Kennedy Capital Management sold 239,054 Esperion Therapeutics shares in Q1 2017, an estimated $2.99M.
  • Kennedy Capital Management first reported a position in Esperion Therapeutics in Q3 2016 and held it in 2 quarters.
  • Kennedy Capital Management's Esperion Therapeutics position peaked at $2.99M in Q4 2016.
  • 119 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2017.

Based on Kennedy Capital Management's 13F filing for Q1 2017, filed 12 May 2017.